Bioverativ Inc.
Customers
0
None disclosed
Suppliers
1
0 disclosed
Latest period
Mar 31, 2018
10-Q filed 2018-05-10
Suppliers 1
Companies that disclose Bioverativ Inc. as a major customer, as a share of their own revenue. 0 active, 1 lapsed.
| Company | % of their revenue | Est. $ from Bioverativ Inc. | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| SGMOQ SANGAMO THERAPEUTICS, INC |
35% | $4.4M | 3M 2018-03-31 | −28.0pp | Lapsed Last seen 2018-03-31 |
10-Q 2018-05-10 |
During the three months ended March 31, 2018, revenues related to the hemophilia A collaboration agreement with Pfizer Inc. (“Pfizer”) and the hemoglobinopathies agreement with Bioverativ, a Sanofi company (“Bioverativ”) represented 61% and 35%, respectively, of the Company’s total revenue. During 2017, revenues related to our collaborative agreements with Pfizer and Bioverativ represented 47% and 34%, respectively, of total revenues. During the three months ended March 31, 2017, revenues related to the Company’s agreements with Bioverativ and Shire International GmBH (“Shire”) represented 63% and 20%, respectively, of total revenue. During 2016, revenues related to our collaborative agreements with Bioverativ, DAS and Shire represented 46%, 26% and 17%, respectively, of total revenues. | ||||||
Alerts are coming
Get an email when Bioverativ Inc.'s disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.